Durvalumab regimens extend PFS in advanced endometrial cancer
Click Here to Manage Email Alerts
The addition of durvalumab to chemotherapy — either alone or in combination with olaparib — improved outcomes for women with advanced endometrial cancer, according to the agent’s manufacturer.
Chemotherapy is standard first-line treatment for women with advanced endometrial cancer; however, long-term outcomes remain poor and more effective treatment options are needed.
Durvalumab (Imfinzi, AstraZeneca) is a human monoclonal antibody that binds to PD-L1. Olaparib (Lynparza; AstraZeneca, Merck) is a poly(ADP-ribose) polymerase (PARP) inhibitor.
The randomized phase 3 DUO-E trial included 699 women with newly diagnosed or recurrent stage III or stage IV epithelial endometrial carcinoma.
The three-arm, double-blind trial assessed first-line durvalumab in combination with platinum-based chemotherapy, followed by maintenance with either durvalumab alone or durvalumab plus olaparib.
Researchers randomly assigned women to 1,120 mg durvalumab or placebo every 3 weeks with standard platinum-based chemotherapy.
After chemotherapy, patients received 1,500 mg durvalumab or placebo every 4 weeks as maintenance therapy, in combination with either 300 mg twice-daily olaparib or placebo. Maintenance continued for 24 months or disease progression.
Both experimental regimens conferred statistically significant PFS benefits compared with chemotherapy alone, according to an AstraZeneca press release. Researchers reported greater benefit with maintenance durvalumab-olaparib than durvalumab alone.
OS data remained immature.
The safety profile of durvalumab plus chemotherapy, as well as the durvalumab-olaparib combination, appeared consistent with the known profiles of the individual agents, according to the release.
Complete results will be submitted for presentation at a medical meeting.
“These exciting data demonstrate durvalumab immunotherapy can significantly delay disease progression for patients with endometrial cancer and the addition of the PARP inhibitor olaparib can improve the benefit further,” Shannon N. Westin, MD, principal investigator of the DUO-E trial and professor of gynecologic oncology and reproductive medicine at The University of MD Anderson Cancer Center, said in the release. “These combinations could provide physicians with new treatment approaches to improve outcomes for patients.”
Read more about
Click Here to Manage Email Alerts